Cargando…

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial

IMPORTANCE: Antiangiogenic drug combinations with anti–programmed cell death 1 protein and anti–programmed cell death 1 ligand 1 (PD-L1) agents are a novel treatment option for lung cancer. However, survival remains limited, and the activity of these combinations for tumors with high tumor mutation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Provencio, Mariano, Ortega, Ana Laura, Coves-Sarto, Juan, Calvo, Virginia, Marsé-Fabregat, Raquel, Dómine, Manuel, Guirado, María, Carcereny, Enric, Fernández, Natalia, Álvarez, Ruth, Blanco, Remei, León-Mateos, Luis, Sánchez-Torres, José Miguel, Sullivan, Ivana Gabriela, Cobo, Manuel, Sánchez-Hernández, Alfredo, Massuti, Bartomeu, Sierra-Rodero, Belen, Mártinez-Toledo, Cristina, Serna-Blasco, Roberto, Romero, Atocha, Cruz-Bermúdez, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856905/ https://www.ncbi.nlm.nih.gov/pubmed/36520426 http://dx.doi.org/10.1001/jamaoncol.2022.5959

Ejemplares similares

Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)
por: Nadal, Ernest, et al.
Publicado: (2023)

Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
por: Franco, Fernando, et al.
Publicado: (2021)

NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment
por: Sánchez‐Herrero, Estela, et al.
Publicado: (2021)

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
por: Provencio, Mariano, et al.
Publicado: (2022)

Lung cancer symptoms at diagnosis: results of a nationwide registry study
por: Ruano-Raviña, Alberto, et al.
Publicado: (2020)

Are there differences by sex in lung cancer characteristics at diagnosis? —a nationwide study
por: Ruano-Ravina, Alberto, et al.
Publicado: (2021)

Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study
por: Provencio, Mariano, et al.
Publicado: (2023)

Cancer as an infective disease: the role of EVs in tumorigenesis
por: Robado de Lope, Lucia, et al.
Publicado: (2022)

Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
por: Gutiérrez, Lourdes, et al.
Publicado: (2021)

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2022)

Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis
por: Sánchez-Herrero, Estela, et al.
Publicado: (2022)

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015
por: García-Campelo, R., et al.
Publicado: (2015)

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
por: Provencio, Mariano, et al.
Publicado: (2022)

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
por: Sierra-Rodero, Belén, et al.
Publicado: (2021)

R-Score: A New Parameter to Assess the Quality of Variants’ Calls Assessed by NGS Using Liquid Biopsies
por: Serna-Blasco, Roberto, et al.
Publicado: (2021)

Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer in the United States
por: Criss, Steven D., et al.
Publicado: (2019)

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2021)

Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study
por: Viñolas, N. Nuria, et al.
Publicado: (2020)

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial
por: Laza‐Briviesca, Raquel, et al.
Publicado: (2021)

Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature
por: Rubio-Perez, Jaime, et al.
Publicado: (2022)

Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020)

Utilidad clínica de la biopsia líquida para el diagnóstico y seguimiento de los pacientes con CPNM y EML4-ALK
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020)

Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation
por: Serna-Blasco, Roberto, et al.
Publicado: (2022)

Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial
por: Shiraishi, Yoshimasa, et al.
Publicado: (2022)

Comprehensive cross‐platform comparison of methods for non‐invasive EGFR mutation testing: results of the RING observational trial
por: Romero, Atocha, et al.
Publicado: (2020)

Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC
por: Hofman, Véronique, et al.
Publicado: (2022)

Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients
por: Provencio, Mariano, et al.
Publicado: (2017)

Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database
por: Campos‐Balea, Begoña, et al.
Publicado: (2020)

Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression
por: Rosell, Rafael, et al.
Publicado: (2009)

Next-generation sequencing to dynamically detect mechanisms of resistance to ALK inhibitors in ALK-positive NSCLC patients: a case report
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020)

Practical Issues in the Use of Atezolizumab for Patients with Non-Small Cell Lung Cancer: Case Reports and Literature Review
por: Cobo, Manuel, et al.
Publicado: (2021)

Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial
por: Kim, Tae Won, et al.
Publicado: (2023)

Escritos económicos : México, 1939-1969
por: Sánchez Sarto, Manuel
Publicado: (2003)

Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study
por: Xu, Bo, et al.
Publicado: (2022)

Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
por: Jantus-Lewintre, Eloisa, et al.
Publicado: (2021)

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
por: Garassino, Marina C., et al.
Publicado: (2023)

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
por: Majem, M., et al.
Publicado: (2018)

ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib
por: Romero, Atocha, et al.
Publicado: (2020)

Transcriptomic analysis of preovipositional embryonic arrest in a nonsquamate reptile (Chelonia mydas)
por: Gárriz, Angela, et al.
Publicado: (2022)

KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor
por: Serna-Blasco, R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pghdkm2l8jnm2695l767hvnkos